Timothy Rolph Akero Therapeutics, Inc. (AKRO) insider trading activity

Timothy Rolph is Chief Scientific Officer of Akero Therapeutics, Inc.. Currently has a direct ownership of 0 shares of AKRO, which is worth approximately $0. The most recent transaction as insider was on Dec 09, 2025, when has been sold 282,149 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

100.0% 3M change

100.0% 12M change

Total Value Held $0

Timothy Rolph Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 09 2025	SELL Sale (or disposition) back to the issuer	-	282,149 Reduced 100.0%	0 Common Stock
Nov 25 2025	BUY Exercise of conversion of derivative security	$1,987,867 $13.02 p/Share	152,678 Added 35.11%	282,149 Common Stock
Nov 17 2025	SELL Bona fide gift	-	37,100 Reduced 22.27%	129,471 Common Stock
Oct 07 2025	SELL Open market or private sale	$580,125 $46.41 p/Share	12,500 Reduced 6.98%	166,571 Common Stock
Oct 07 2025	BUY Exercise of conversion of derivative security	$354,375 $28.35 p/Share	12,500 Added 6.52%	179,071 Common Stock
Sep 11 2025	SELL Open market or private sale	$23,790 $43.02 p/Share	553 Reduced 0.33%	166,571 Common Stock
Sep 08 2025	SELL Open market or private sale	$556,625 $44.53 p/Share	12,500 Reduced 6.96%	167,124 Common Stock

Sep 08 2025	BUY Exercise of conversion of derivative security	$232,500 $18.6 p/Share	12,500 Added 6.51%	179,624 Common Stock
Aug 05 2025	SELL Open market or private sale	$616,000 $49.28 p/Share	12,500 Reduced 6.96%	167,124 Common Stock
Aug 05 2025	BUY Exercise of conversion of derivative security	$263,625 $21.09 p/Share	12,500 Added 6.51%	179,624 Common Stock
Jul 07 2025	SELL Open market or private sale	$648,125 $51.85 p/Share	12,500 Reduced 6.96%	167,124 Common Stock
Jul 07 2025	BUY Exercise of conversion of derivative security	$263,625 $21.09 p/Share	12,500 Added 6.51%	179,624 Common Stock
Jun 30 2025	BUY Grant, award, or other acquisition	$21,244 $23.87 p/Share	890 Added 0.53%	167,124 Common Stock
Jun 18 2025	SELL Open market or private sale	$61,914 $54.84 p/Share	1,129 Reduced 0.67%	166,234 Common Stock
Jun 10 2025	SELL Open market or private sale	$127,332 $54.0 p/Share	2,358 Reduced 1.39%	167,363 Common Stock
Jun 06 2025	SELL Open market or private sale	$1,376,000 $55.04 p/Share	25,000 Reduced 12.84%	169,721 Common Stock
Jun 06 2025	BUY Exercise of conversion of derivative security	$527,500 $21.1 p/Share	25,000 Added 11.38%	194,721 Common Stock
Jun 05 2025	SELL Open market or private sale	$670,125 $53.61 p/Share	12,500 Reduced 6.86%	169,721 Common Stock
Jun 05 2025	BUY Exercise of conversion of derivative security	$263,750 $21.1 p/Share	12,500 Added 6.42%	182,221 Common Stock
May 06 2025	SELL Open market or private sale	$544,250 $43.54 p/Share	12,500 Reduced 6.86%	169,721 Common Stock
May 06 2025	BUY Exercise of conversion of derivative security	$263,750 $21.1 p/Share	12,500 Added 6.42%	182,221 Common Stock
Apr 24 2025	SELL Open market or private sale	$256,437 $41.03 p/Share	6,250 Reduced 3.55%	169,721 Common Stock
Apr 24 2025	BUY Exercise of conversion of derivative security	$131,875 $21.1 p/Share	6,250 Added 3.43%	175,971 Common Stock
Apr 07 2025	SELL Open market or private sale	$228,500 $36.56 p/Share	6,250 Reduced 3.55%	169,721 Common Stock
Apr 07 2025	BUY Exercise of conversion of derivative security	$131,875 $21.1 p/Share	6,250 Added 3.43%	175,971 Common Stock

Timothy Rolph

Chief Scientific Officer

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKRO shares.

Notify only if

Value

Insider Trading

Get notified when an Akero Therapeutics, Inc. insider buys or sells AKRO shares.

Notify only if

Operation

Value

Type

News

Receive news related to Akero Therapeutics, Inc.

Track Activities on AKRO

Account